AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
AgNovos Healthcare is pleased to announce an exclusive option agreement with Asahi Kasei Pharma Corporation.
AgNovos Healthcare will participate in this year’s virtual Fragility Fracture Network Congress from September 28-30th.
AgNovos will participate in this year’s Swiss Association Against Osteoporosis continuing education day on metabolic bone disease on September 23 in Bern, Switzerland.
AgNovos Healthcare will participate in this year’s British Orthopaedic Association Congress from September 21-24 in Aberdeen, Scotland.
AgNovos Healthcare will participate in this year’s European Hip Society Congress in Lille, France from September 10-11.
AgNovos Healthcare will sponsor a webinar hosted by the International Osteoporosis Foundation on September 7th titled “FRAX and the Future of Risk Assessment.”